Destiny Pharma, one of our longstanding clients, featured in the April 2023 edition of MedNous, the specialist medical research journal. Neil Clark, CEO, and Dr Bill Love, Founder and CSO, sat down with Victoria English to discuss the fantastic progress that has been made with Destiny’s two lead assets, XF-73, a nasal gel for the treatment […]
Brighton, United Kingdom – 4 April 2023 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces that data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, to successfully colonise the gut following administration […]
Exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals® worth up to $570m plus royalties Partnership with Sebela will finance the future clinical development and commercialization costs of NTCD-M3 in North America Destiny Pharma retains majority rights for Europe and ROW Key strategic target achieved for NTCD-M3 Brighton, United Kingdom – 24 February 2023 – […]
Brighton, United Kingdom – 25 January 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, notes an increased focus on the importance of infection prevention by the Center for Disease Control (“CDC”), Food and Drug Administration (“FDA”), and the medical community in […]
Brighton, United Kingdom – 4th November 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that its Scientific Advisory Board Member, Professor Dale Gerding, MD, MACP, FIDSA, FSHEA, will be giving a keynote presentation at the C. diff International Conference & Health EXPO […]
